Miozac (Dobutamine Hydrochloride)

• Dobutamine acts as a beta‑1 adrenergic inotrope to improve cardiac performance in acute circulatory disorders.
• Acute heart failure: enhances cardiac output and reduces symptoms of low perfusion.
• Cardiogenic shock: restores hemodynamic stability by increasing contractility and blood pressure.
• Low cardiac output states: supports circulation when other inotropes are inadequate.

• Dobutamine binds selectively to β1‑adrenergic receptors on myocardial cells, activating adenylate cyclase via Gs proteins. The resulting rise in intracellular cyclic AMP enhances calcium influx during systole, which strengthens myocardial contraction (positive inotropy) and modestly increases heart rate. This pharmacologic action raises stroke volume and cardiac output without significant peripheral vasoconstriction. The effect is dose‑dependent and rapidly reversible upon discontinuation, allowing clinicians to titrate therapy to the desired hemodynamic response.

Dobutamine may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Tachycardia: rapid increase in heart rate that may be symptomatic.
• Hypertension: elevated blood pressure, sometimes requiring monitoring.
• Headache: mild to moderate head discomfort occurring during infusion.
• Nausea: feeling of sickness or urge to vomit, often transient.

Serious or Rare Side Effects

• Myocardial ischemia: reduced blood flow to heart muscle that can cause chest pain.
• Severe arrhythmias: life‑threatening irregular heart rhythms such as ventricular tachycardia.
• Pulmonary edema: fluid accumulation in the lungs leading to breathing difficulty.
• Anaphylactic reaction: severe allergic response with rash, swelling, and possible airway compromise.

When using Dobutamine, careful clinical monitoring and specific precautions are essential to ensure patient safety.

• Cardiac monitoring: continuous ECG and arterial pressure monitoring should be maintained during infusion.
• Dose titration: adjust infusion rate based on hemodynamic response and target parameters.
• Renal impairment: monitor fluid balance and electrolytes closely in patients with kidney dysfunction.
• Concomitant vasopressors: use with caution as combined effects may alter blood pressure.
• Pregnancy: consider only if potential benefits justify potential risks to the fetus.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Dobutamine can interact with several medications, affecting its efficacy or safety profile.

Major Interactions (Avoid)

• Beta‑blockers: may blunt Dobutamine’s inotropic effect, reducing therapeutic benefit.
• MAO inhibitors: increase risk of hypertensive crisis when combined.
• Tricyclic antidepressants: elevate risk of arrhythmias during therapy.
• Non‑dihydropyridine calcium channel blockers: may potentiate negative inotropic actions.

Moderate Interactions (Monitor Closely)

• Diuretics: electrolyte shifts can modify cardiac response to Dobutamine.
• ACE inhibitors: additive hypotensive effect may require blood pressure monitoring.